Qilian International Holding Group Limited

Qilian International Holding Group Limited

QLI
Qilian International Holding Group LimitedUS flagNASDAQ Global Market
5.41
USD
-0.20
- -
38.68MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
0.64
1.44
1.32
1.43
1.68
1.81
- -
Basic EPS, GAAP
0.04
0.15
0.15
0.14
0.09
0.03
- -
Free Cash Flow per Basic Share
0.03
0.09
-0.03
0.13
-0.09
0.26
- -
Dividend per Share
- -
0.02
- -
- -
- -
- -
- -
Book Value per Share
0.09
0.08
0.22
0.35
0.43
0.44
- -
Tangible Book Value per Share
0.33
0.45
0.59
0.77
1.61
1.49
- -
Basic Weighted Avg Shares
35
35
35
35
34
36
- -
Sales/Revenue/Turnover
23
50
46
50
57
65
46
Operating Margin (%)
5.02
11.86
15.21
11.78
5.17
3.88
-5.2
Depreciation Expense
1
1
1
1
1
1
1
Net Income, GAAP
1
5
5
5
3
1
-8
Effective Tax Rate (%)
17.29
15.35
14.89
14.9
7.59
12.45
- -
Profit Margin (%)
6.28
10.26
11.57
10.12
5.52
1.66
-16.74
Working Capital
4
8
13
19
22
21
28
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
14
18
23
29
57
55
44
Return on Invested Capital (%)
- -
22.82
23.4
15.32
5.33
3.6
- -
Return on Capital (%)
- -
48.35
39.89
28.51
13.78
3.59
- -
Return on Common Equity (%)
- -
171.59
101.28
51
23.35
7.1
-72.29

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.86%
-19.31%
Free Cash Flow
- -
-264.91%
-136.21%
Net Income, GAAP
- -
-185.62%
-822.64%
Sales/Revenue/Turnover
- -
-0.12%
-28.35%
Total Cash Common Dividend
- -
- -
143.55%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
57
2022
- -
- -
- -
- -
65
2023
- -
- -
- -
- -
46

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
0.09
2022
- -
- -
- -
- -
0.03
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Chen Xin
Full Time Employees
298
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Jiuquan Eco & Tech Dev Zn Jiuquan People's Republic of China 735000
IPO Date
Jan 12, 2021
Website
qlsyy.net
Business
BGM Group Ltd., formerly Qilian International Holding Group Limited, manufactures and markets pharmaceutical and chemical products in China. The company develops, produces and sells licorice products including Gan Di Xin antitussive and expectorant tablets, Qilian Shan licorice extract and liquid extract; oxytetracycline products such as Qilian Shan oxytetracycline tablets and active pharmaceutical ingredients; traditional Chinese medicine derivatives (TCMD) like Ahan antibacterial paste; heparin sodium preparations; Zhu Xiaochang sausage casings; and Xiongguan organic and organic-inorganic compound fertilizers. Qilian International Holding Group Limited, founded in 2019 and headquartered in Jiuquan, Gansu Province, China, operates through segments encompassing oxytetracycline and licorice products with TCMD, fertilizers, and heparin products with sausage casings, serving customers across more than 20 provinces in China. In recent strategic shifts, the company announces a name change to BGM Group Ltd. effective following an extraordinary general meeting on October 18, 2024, and changes its Nasdaq ticker symbol from QLI to BGM effective August 11, 2024; implements a 1-for-5 reverse share split effective June 21, 2024; regains Nasdaq minimum bid price compliance in July 2024; and adjusts industrial investments by reducing oxytetracycline focus while expanding heparin sodium, licorice products, financial technology and software development. BGM Group pursues aggressive expansion through multiple acquisitions including HM Management Company Limited in an all-stock deal valued at CNY 300 million completed June 2024, YX Management Company Limited in April 2024, Wonder Dragon Global Limited in May 2024, Patriton Limited via reverse merger in January 2025, and RONS Intelligent Technology and Shenzhen Xinbao Investment from AIX Inc. in December 2024, alongside agreements to acquire Xingdao Intelligent Cloud Chain and YD Network Technology for $111.2 million announced May 2025, shifting toward AI, intelligent platforms and diversified sectors beyond traditional pharmaceuticals. The company, rebranded as an innovative entity headquartered in Chengdu, China, employs approximately 283 full-time staff and listed on Nasdaq via IPO in January 2021.

Company News

APIChatGPT
  • Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

  • Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

  • Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

  • Qilian International plans to adjust industrial investment

  • Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

  • Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  • Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021

  • Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone

  • Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in Chongqing

  • QLI Stock Price Increased Over 10% Pre-Market: Why It Happened

  • Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results

  • Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021

  • U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week

  • Qilian International Holding Group Limited Announces Closing of Initial Public Offering